Molecular Oncology Diagnostics Market by Product, Technology, Cancer Type, End User

Description

List of Tables

[180 Pages Report] The Molecular Oncology Diagnostics Market size was estimated at USD 8.84 billion in 2023 and expected to reach USD 9.88 billion in 2024, at a CAGR 11.83% to reach USD 19.36 billion by 2030.

Global Molecular Oncology Diagnostics Market

KEY MARKET STATISTICS
Base Year [2023]	USD 8.84 billion
Estimated Year [2024]	USD 9.88 billion
Forecast Year [2030]	USD 19.36 billion
CAGR (%)	11.83%

Molecular Oncology Diagnostics Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Molecular Oncology Diagnostics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Molecular Oncology Diagnostics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Molecular Oncology Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., Bayer AG, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biocartis NV, Biocept, Inc., BIOMERIEUX SA, Danaher Corporation, DiaSorin Molecular LLC, Enzo Biochem, Inc., F. Hoffmann-La Roche Ltd., GenMark Saglik, Hologic, Inc., Illumina, Inc., Leica Biosystems Nussloch GmbH, Myriad Genetics, Inc., NeoGenomics Laboratories, OncoCyte Corporation, PathAI, Inc., Personal Genome Diagnostics Inc., QIAGEN N.V., Siemens AG, Sysmex Asia Pacific Pte Ltd., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Molecular Oncology Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
- Instruments
- Reagents
Technology
- Chips & Microarrays
- In Situ Hybridization
- Isothermal Nucleic Acid Amplification Technology (INAAT)
- Mass Spectrometry
- Multiplex
- PCR
- Sequencing
- Transcription Mediated Amplification
Cancer Type
- Blood Cancer
- Breast Cancer
- Cervical Cancer
- Colorectal Cancer
- Kidney Cancer
- Liver Cancer
- Lung Cancer
- Prostate Cancer
End User
- Diagnostic Centers
- Hospitals
Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Molecular Oncology Diagnostics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Molecular Oncology Diagnostics Market?

3. What are the technology trends and regulatory frameworks in the Molecular Oncology Diagnostics Market?

4. What is the market share of the leading vendors in the Molecular Oncology Diagnostics Market?

5. Which modes and strategic moves are suitable for entering the Molecular Oncology Diagnostics Market?

Product Code: MRR-5C6F41F5AFFB

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Molecular Oncology Diagnostics Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing prevalence of cancer cases and aging population
  - 5.1.1.2. Rising need for automated and advanced diagnostic techniques
  - 5.1.1.3. Favorable health reimbursement and the trend toward personalized medicine
- 5.1.2. Restraints
  - 5.1.2.1. High cost associated with molecular oncology diagnostics test
- 5.1.3. Opportunities
  - 5.1.3.1. Ongoing investments in R&D activities in oncology diagnostics
  - 5.1.3.2. Technological advancements in molecular biology and biotechnology
- 5.1.4. Challenges
  - 5.1.4.1. Stringent regulatory hurdles coupled with a lack of consistent standards in molecular diagnostic techniques
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Molecular Oncology Diagnostics Market, by Product

6.1. Introduction
6.2. Instruments
6.3. Reagents

7. Molecular Oncology Diagnostics Market, by Technology

7.1. Introduction
7.2. Chips & Microarrays
7.3. In Situ Hybridization
7.4. Isothermal Nucleic Acid Amplification Technology (INAAT)
7.5. Mass Spectrometry
7.6. Multiplex
7.7. PCR
7.8. Sequencing
7.9. Transcription Mediated Amplification

8. Molecular Oncology Diagnostics Market, by Cancer Type

8.1. Introduction
8.2. Blood Cancer
8.3. Breast Cancer
8.4. Cervical Cancer
8.5. Colorectal Cancer
8.6. Kidney Cancer
8.7. Liver Cancer
8.8. Lung Cancer
8.9. Prostate Cancer

9. Molecular Oncology Diagnostics Market, by End User

9.1. Introduction
9.2. Diagnostic Centers
9.3. Hospitals

10. Americas Molecular Oncology Diagnostics Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Molecular Oncology Diagnostics Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Molecular Oncology Diagnostics Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player

14. Competitive Portfolio

14.1. Key Company Profiles
- 14.1.1. Abbott Laboratories
- 14.1.2. Agilent Technologies, Inc.
- 14.1.3. Bayer AG
- 14.1.4. Becton, Dickinson and Company
- 14.1.5. Bio-Rad Laboratories, Inc.
- 14.1.6. Biocartis NV
- 14.1.7. Biocept, Inc.
- 14.1.8. BIOMERIEUX SA
- 14.1.9. Danaher Corporation
- 14.1.10. DiaSorin Molecular LLC
- 14.1.11. Enzo Biochem, Inc.
- 14.1.12. F. Hoffmann-La Roche Ltd.
- 14.1.13. GenMark Saglik
- 14.1.14. Hologic, Inc.
- 14.1.15. Illumina, Inc.
- 14.1.16. Leica Biosystems Nussloch GmbH
- 14.1.17. Myriad Genetics, Inc.
- 14.1.18. NeoGenomics Laboratories
- 14.1.19. OncoCyte Corporation
- 14.1.20. PathAI, Inc.
- 14.1.21. Personal Genome Diagnostics Inc.
- 14.1.22. QIAGEN N.V.
- 14.1.23. Siemens AG
- 14.1.24. Sysmex Asia Pacific Pte Ltd.
- 14.1.25. Thermo Fisher Scientific Inc.
14.2. Key Product Portfolio

15. Appendix

15.1. Discussion Guide
15.2. License & Pricing